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Abstract
Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated
from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for
treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter
(>4.5&) were associated with a twofold higher risk of relapse.
Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients
with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter
1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharma-
cogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials
and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase
CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid
standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference
gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression
analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results:
The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54% (95% confidence interval [CI], 46%-62%).
ABCG2 expression (&) was retained as the only significant variable (P ¼ .02; hazard ratio, 1.04; 95% CI, 1.01-1.07) in1Department of Hematology and Oncology, University Hospital Mannheim, Heidel-
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multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P ¼ .04).
Patients with an ABCG2/GUSB transcript level >4.5& (n ¼ 93) showed a 12-month TFR rate of 47% (95% CI, 37%-
57%), whereas patients with low ABCG2 expression (4.5&; n ¼ 39) had a 12-month TFR rate of 72% (95% CI, 55%-
82%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment
discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 4, 266-71 ª 2018 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ABCG2, Biomarker, CML, Imatinib, PredictionIntroduction
Tyrosine kinase inhibitor (TKI) discontinuation in chronic
myeloid leukemia (CML) constitutes an important pillar in future
CML treatment.1 Several studies showed that TKIs can safely be
discontinued in CML patients with sustained deep molecular
response (DMR).2-4 So far, DMR and treatment duration were
shown to be predictive for successful treatment-free remission
(TFR) whereas age, risk scores, and sex were not known to have an
influence.3 In addition, molecular levels of DMR (molecular
response 4-log reduction [MR4], molecular response 4.5-log
reduction) were not reported to be predictive for TFR.2,5 Until
now, TFR biomarker research focused mainly on immune surveil-
lance and immune exhaustion. Natural killer cells and CD86þ cells
proved to be predictive for relapse-free survival.6-8 However, the
effect of pharmacogenetic factors has not yet been analyzed in the
recent context of discontinuation trials.
The breast cancer resistance protein (ABCG2), organic cation
transporter 1 (OCT1), and multidrug resistance protein (ABCB1)
gene products are known to play a crucial role in acquired pharma-
cokinetic drug resistance and DMR in nilotinib, imatinib, and
dasatinib treatment of CML patients.9,10 The human organic cation
transporter 1 (OCT1, human organic cation transporter 1, or solute
carrier family 22 member 1) is involved in the absorption, distribu-
tion, and elimination of endogenous compounds, toxins, and other
xenobiotics that are positively charged at physiological pH.11 OCT1
activity was shown to predict overall survival and TKI response in
CML patients.12,13 Some studies showed that its gene expression
predicts TKI response14 pp 1,15 but the results could not be reproduced
in several other studies.16,17 Thus, this correlation is still a matter of
debate. ABCB1 (P-glycoprotein, multidrug resistance protein 1
[MDR1]) and ABCG2 (breast cancer resistance protein) are 2
members of the adenosine triphosphate-binding cassette family of
membrane transporters, prominent for their role in multidrug resis-
tance. Imatinib, dasatinib, and nilotinib were shown to be substrates as
well as competitive inhibitors in different extents.18-23 ABCB1
expression has been reported to predict TKI response.23-25 pp 1 A recent
meta-analysis showed that ABCG2 polymorphisms were potential
CML response predictors.26 In this study, we aimed to investigate
whether aberrant gene expression of these influx and efflux channels
predispose for CML relapse after TKI discontinuation.
Methods
Samples and Study Design
This analysis included 132 CML patients from the European
Stop Tyrosine Kinase Inhibitor Study (EURO-SKI) trial, aprospective multicenter TKI discontinuation trial
(NCT01596114).3 In accordance with the Declaration of Helsinki,
written informed consent was obtained from all patients. According
to the EURO-SKI inclusion criteria, patients with MR4 duration of
at least 1 year and TKI treatment of at least 3 years were enrolled.
TFR is on the basis of survival without loss of major molecular
response and is expressed as molecular relapse-free survival rate in
the KaplaneMeier analysis.
Gene expression analyses were performed on leukocyte RNA
isolated from peripheral blood samples of patients screened in our
center and 10 healthy individuals (male n ¼ 5; female n ¼ 5) served
as controls. Blood samples were collected at the last day of TKI
intake (baseline).
Molecular Analysis
The gene expression levels of breakpoint cluster region (BCR)-
Abelson murine leukemia viral oncogene homolog (ABL) and
ABL1 were determined using quantitative real-time polymerase
chain reaction (qRT-PCR) from total leukocyte RNA of periph-
eral blood samples. BCR-ABL transcript levels were measured
using standard plasmid dilutions, as described previously.27 Ratios
derived from BCR-ABL/ABL1 were converted to the Interna-
tional Scale.
The qRT-PCR reactions for quantifying ABCB1, ABCG2,
OCT1, and GUSB (beta-glucuronidase 1, reference gene) consisted
of (per 20-mL reaction mix): 4 mL LightCycler 480 Probes Master
Mix (Roche Diagnostics, Indianapolis, IN), 0.5 mL reverse primer,
0.5 mL forward primer, 0.25 mL anchor probe, 0.25 mL sensor
probe (TIB Molbiol, Berlin, Germany), and 2 mL cDNA or
plasmid dilution (see Supplemental Table 1 in the online version:
primer sequences). The cycle settings were the following: 10 mi-
nutes denaturation at 95C, 40 cycles of 10-second denaturation at
95C, 20 seconds annealing at 60C, and 30 seconds elongation at
72C.
Cloning of Plasmid Standards
The plasmid was cloned by transforming and cultivating
Escherichia coli one shot Top10F’ (Invitrogen, Carlsbad, CA). The
preparation of the plasmid DNA was done using HiSpeed Plasmid
Maxi Kit (Qiagen, Hilden, Germany). Plasmid linearization was
performed using the Xbal restriction enzyme. For absolute quanti-
fication of the ABCB1, ABCG2, and OCT1 transcript levels, the
5-log series of plasmid dilutions were amplified using qRT-PCR.
For this reason, the pEX-A2 plasmid design (ID: 3321214, Euro-
fins, Luxembourg) contained an 861-base pair insert, on the basis ofClinical Lymphoma, Myeloma & Leukemia April 2018 - 267
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268 -subgenic stretches of ABCB1, ABCG2, OCT1, and GUSB (reference
gene) with their specific primer sequences.
The 5-log plasmid dilutions with a range from 40 to 400,000
transcripts were detected in all qRT-PCR runs. ABCG2, ABCB1,
and OCT1 transcripts were detectable in every sample and their
expression rate is presented as “gene of interest/GUSB” ratio.
Statistical Analysis
The hazard ratio (HR) of the efflux and influx channel transcript
levels was estimated using Cox regression analysis. Significance was
determined using the Wald test. Cutoffs for ABCG2, OCT1, and
ABCB1 were sought for in 10,000 bootstrap samples of size n ¼
132.28 In line with the minimal P value approach, within each
sample the log-rank test was used to identify a threshold that
separated 2 groups of patients with most different relapse proba-
bilities.29 While adjusting for multiple testing using the Bonferroni
correction for a candidate threshold, the differences in the relapse
probabilities of the resulting groups had to be statistically signifi-
cant.30 Association between variables was analyzed using the
ManneWhitney U test or Spearman rank correlation coefficient,
whichever was applicable. Two related samples were compared
using the Wilcoxon signed rank test. Relapse was defined as the first
loss of major molecular response at any time. The study has an
exploratory character. Apart from cutoff selection using the minimal
P value method, multiplicity was not considered. For the 2-sided
P values, the unadjusted significance level of .05 was applied to
all statistical tests. Calculations were done using SAS (version 9.4,
SAS Institute Inc, Cary, NC), the programming software R (version
3.2.2, R Foundation for Statistical Computing, Vienna, Austria),
and SPSS (version 20, IBM Corp, Armonk, NY). To identify a
minimal P value, the R package “party” (version 1.0-25) was
applied.Figure 1 Molecular Relapse-Free Survival Probabilities of 132
EURO-SKI Patients. After 12 Months, the Survival
Probability Was 54% (95% CI, 46%-62%). Median
Observation Time Was 17 Months
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Patient Characteristics
In our cohort, 132 chronic phase CML patients discontinued
TKI treatment. The molecular relapse-free survival rate at 12
months resulted in 54% (95% confidence interval [CI], 46%-62%;
Figure 1). Median observation time was 17 months. Median of
MR4 and TKI treatment duration was 4.3 and 7.6 years, respec-
tively. Patients were exclusively treated with imatinib. Further
patient characteristics are summarized in Table 1.
ABCB1, ABCG2, and OCT1 Expression Levels
Throughout the cohort, ABCB1 showed the highest gene
expression in peripheral blood leukocytes (70%; range, 18-512)
whereas ABCG2 showed the lowest transcripts levels (0.7%; range,
0-4). Twelve months after TKI discontinuation, the efflux trans-
porters ABCG2 as well as ABCB1 and the influx transporter OCT1
presented no significant differences between relapsed and non-
relapsed patients (P > .05). The comparison with healthy controls
revealed significant overexpression of ABCB1 (P < .03) and
suppression of OCT1 (P < .03) transcripts in chronic phase CML
patients (Figure 2). The efflux transporter ABCG2 showed no
significant changes in gene expression between EURO-SKI patients
and healthy controls (Figure 2A).
We further investigated the effect of TKI withdrawal upon gene
expression. After TKI discontinuation, in 40 patients analyzed, a
significant downregulation of ABCB1 at the day of relapse was
shown (P ¼ .017; Figure 3C). The other channels showed no such
transcript level adaption after imatinib discontinuation (P > .05;
Figure 3A and B).
Multiple Regression Analyses, Cutoff Investigation, and
Risk Stratification
Prognostic significance of transcript levels was assessed using
multiple Cox regression analysis, considering age and sex as well as
the clinically relevant factors MR4 duration and TKI duration as
candidate variables. Prognostic scores (eg, European Treatment and
Outcome Study, Sokal, Euro, and European Treatment and
Outcome Study long-term survival) could not be considered
because they were not sufficiently documented. ABCG2 expression
(&) was retained as the only significant variable in the model (P ¼
.02; HR, 1.04; 95% CI, 1.01-1.07). Adjusted for multiple testing
and most often chosen in the bootstrap samples, the thresholdTable 1 Clinicopathologic Characteristics of the 132 EURO-SKI
Patients
Patient Characteristic
Median Value (Range) or
Percentage
Age, Years 62 (27-87)
Male Sex 52
TKI Duration, Years (n ¼ 130) 7.6 (3-14)
MR4 Duration, Years 4.3 (1-13)
ABCG2 Expression, % 0.7 (0-4)
OCT1 Expression, % 4.1 (0.2-26)
ABCB1 Expression, % 70 (18-512)
Abbreviations: EURO-SKI ¼ European Stop Tyrosine Kinase Inhibitor Study trial; MR4 ¼ mo-
lecular response 4-log reduction; TKI ¼ tyrosine kinase inhibitor.
Figure 2 Transcript Levels of ABCG2 (A), OCT1 (B), and ABCB1 (C) of Patients at the Last Day of Tyrosine Kinase Inhibitor (TKI) Intake
(Baseline) Compared With Healthy Individuals (n [ 10). Patients Were Divided Into 2 Groups: 1 Group With Loss of Major
Molecular Response Within 12 Months After Discontinuation of Therapy and 1 Group Without Loss. P Values Refer to the
Comparison of Each Patient Group With the Healthy Controls Using the ManneWhitney U Test
Sébastien Rinaldetti et al4.5& resulted in a significant risk stratification for the ABCG2
efflux transporter (P ¼ .04; Figure 4). Patients with an ABCG2/
GUSB transcript level >4.5& (n ¼ 93) had a 12-month relapse-
free survival rate of 47% (95% CI, 37%-57%), whereas patients
with lower ABCG2 expression (4.5&; n ¼ 39) showed a 12-
month TFR of 72% (95% CI, 55%-82%; Figure 4). ABCG2/
GUSB transcript level >4.5& showed approximately a twofold
higher risk of relapse after treatment discontinuation (HR, 1.92;
95% CI, 1.02-3.61). Cutoff analysis of OCT1 and ABCB1 pro-
vided no gene expression threshold with significant risk
stratification.
All genes were tested for correlation with the BCR-ABL inter-
national scale transcript level before stopping as well as with TKI
and MR4 duration. No significant correlation was found (Spearman
correlation P > .05).
Discussion
The present study was designed to determine the effect of
pharmacogenetics on response after CML treatment discontinua-
tion. On the basis of our findings, ABCG2 expression as opposed toFigure 3 Transcript Levels of ABCG2 (A), OCT1 (B) and ABCB1 (C) o
Discontinuation and on the Day of Loss of Major Molecula
Using the Wilcoxon Signed Rank TestOCT1 and ABCB1 (MDR1) was an independent predictor of TFR
after TKI discontinuation. Accordingly, patients with a high
expression of the ABCG2 efflux transporter (>4.5&) were shown
to have a twofold higher risk of relapse. These findings seem to be
reasonable from a biological point of view, according to the hy-
pothesis that a higher gene expression of ABCG2 might increase
TKI efflux on the protein level and impair treatment.
In- and efflux transporter expression analyses of CML patients
after long-term TKI treatment (median TKI duration, 7.6 years;
median DMR duration, 4.3 years) have not been reported in the
literature before. The results of this study showed that patients in
DMR presented a different expression level of ABCB1 and OCT1,
compared with healthy controls.
The overexpression of ABCB1 (MDR1) and suppression of
OCT1 might confer a survival or selection advantage. ABCB1
seemed to respond most sensitively to TKI exposure, because
imatinib withdrawal led to a significant downregulation or
normalization of its transcript levels. In contrast, the expression of
ABCG2 was similar to healthy controls. An in vivo study showed
that ABCG2 is indirectly regulated by thephosphatidylinositol-4,5-f EURO-SKI Patients (n [ 40) on the Day of Treatment
r Response. P Values Refer to the Comparison of the 2 Groups
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Figure 4 Molecular Relapse-Free Survival Probabilities of 132
EURO-SKI Patients Stratified in Accordance With
Their ABCG2/GUSB Ratio on the Day of Treatment
Discontinuation. Patients With ABCG2/GUSB Ratio
>4.5& (Red) Showed a Higher Risk of Relapse
Comparison With Patients With ABCG2
Transcripts £4.5& (P [ .04, Log Rank Test)
Abbreviation: TKI ¼ tyrosine kinase inhibitor.
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270 -bisphosphate 3-kinase, RAC-alpha serine/threonine-protein kinase
pathway, which is inhibited by imatinib-induced reduction of
phosphorylated RAC-alpha serine/threonine-protein kinase.31 pp 2
Inhibition of this pathway led to a post-transcriptional reduction
of ABCG2 protein expression. An in vitro long-term exposure study
showed a decrease in ABCG2 transcript level over time in K562
cells upon imatinib and dasatinib exposure.32 In the present study
most BCR-ABL positive cells had likely been eradicated and
“normal” hematopoiesis was analyzed. The effect of TKI long-term
exposure on in- and efflux transporters in BCR-ABL negative cells is
yet not well understood. Our data confirmed the lack of auto-
induction of ABCG2 after long-term imatinib exposure, as shown
by Gardner et al in a murine model.33 This study further presented
a decline of ABCG2 protein expression after weeks of TKI exposure
in liver and intestinal tissue. A possible explanation might be a TKI-
mediated enhanced ABCG2 mRNA lysosomal degradation.34,35
In- and efflux transporter expression did not correlate with TKI and
MR4 duration. Concerning ABCB1, recent data showed that a high-
fold rise of the ABCB1 mRNA expression from diagnosis to day 22
of imatinib therapy predicted patient response.24 Thus our data cannot
exclude a possible correlation between the in- and efflux transporter
expression and TKI and MR4 duration, because aberrant OCT1 and
ABCB1 expression might develop early upon TKI exposure and cor-
relation might get lost after years of MR4 and TKI treatment.Clinical Lymphoma, Myeloma & Leukemia April 2018With regard to the ABCG2 gene expression, we showed that
differential expression of a noninvasive biomarker can be
detected using a sensitive quantification method on the basis of
plasmid standards and may be used for TFR prediction. How-
ever, our findings need further validation by an independent
cohort. Indeed, patients with high ABCG2 expression showed
similar TFR rates (47%) than the overall study population
(54%). However, patients with low ABCG2 expression may be
eligible for shorter TKI treatment duration before therapy
discontinuation. Furthermore, the impact of the in- and efflux
transporters has to be reevaluated separately for each TKI. To
improve the prediction of relapse-free survival, we suggest
ABCG2 be integrated in a multiple marker panel, because gene
signatures might better reflect the multifactorial process of TFR.
Conclusion
This study was set out with the aim of investigating the effect of
pharmacogenetics in a CML treatment discontinuation trial.
ABCG2 gene expression as opposed to OCT1 and ABCB1 (MDR1)
predicted TFR after TKI discontinuation. High transcript levels of
the ABCG2 efflux transporter (>4.5&) were associated with a
twofold higher risk of relapse.
Clinical Practice Points
 To date there exist no non-invasive molecular biomarkers pre-
dicting treatment-free remission after TKI discontinuation. In
addition, it is little known about the pharmacogenomics in TKI
discontinuation.
 The results of this study showed that patients in DMR after several
years of TKI treatment presented differential expression of ABCB1
andOCT1, compared to healthy controls. However, only ABCG2
was predictive for treatment-free remission in Cox regression
analysis. High transcript levels of the ABCG2 efflux transporter
(>4.5&) were associated with a twofold higher risk of relapse.
 ABCG2 may be a valuable biomarker to be integrated in a
multiple marker screening for TFR prediction.Acknowledgments
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